Main information
- Oral drugs could be a major asset in the fight against obesity in low -income countries.
- Oral drugs could change the situation in the fight against obesity and diabetes in countries with low and medium income.
- OrForglipron, a daily pill, seems promising to reduce blood sugar and promote weight loss comparable to that of injectable GLP-1 receptors.
- Targeted weight management strategies are necessary for various populations due to the complex interaction between ethnicity and obesity diseases.
The new oral weight loss drugs are promising in the fight against obesity and diabetes in low and intermediate income countries. Although drug loss injectable, such as Wegovy and Mounjaro have shown impressive results in reducing body weight and diabetes management, their high cost, their complex administration and refrigeration requirements limit their accessibility in these regions.
- Experts believe that oral drugs could change the situation.
They would be cheaper, easier to transport and store, and meet the critical need for effective treatments against obesity in low and intermediate income countries where the rates of these diseases increase rapidly. These oral drugs imitate GLP-1, a hormone that regulates appetite and insulin production, resulting in weight loss and better control of blood sugar.
Testing
Orforglipron, a daily pill that is currently the subject of clinical trials, is one of those drugs that arouse enthusiasm. The first results suggest that its effectiveness in reducing blood sugar and promoting weight loss is comparable to that of semaglutide, an existing GLP-1 receptor agonist. OrForglipron has certain advantages compared to the semaglutide administered orally, because it can be taken with food, which potentially requires lower doses and therefore makes it more profitable.
-Other research is underway to confirm the safety profile of orforglipron and assess its impact on cardiovascular health. Although the long -term advantages are still under study, experts are optimistic about the potential of orforglipron and other similar drugs to contribute significantly to the fight against the growing epidemic of obesity on a global scale.
Various strategies by ethnicity
The need for such drugs is underlined by the complex interaction between ethnicity and obesity -related diseases. Studies have shown that certain ethnic groups, such as South Asians and Blacks, are more likely to develop type 2 diabetes with lower body weight than white populations. It is therefore urgent to implement effective weight management strategies adapted to various populations.
If you want to access all the articles, subscribe here!
